2-环丙基乙酰胺 | 89580-05-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-环丙基乙酰胺
• 英文名称: 2-cyclopropylacetamide
• CAS: 89580-05-2
• 化学式: C₅H₉NO
• mdl: MFCD11644102
• 分子量: 99.1326
• InChiKey: JBSLANHIBKBQGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-环丙基乙酰胺 在 lithium aluminium tetrahydride 作用下， 生成 2-环丙基乙胺
  参考文献：
  名称：

  The Reaction of 2-Cyclopropylethylamine-1-¹⁴C with Nitrous Acid

  摘要：

  DOI：

  10.1021/ja00890a022
• 作为产物：
  描述：

  环丙乙酸 在 N,N'-羰基二咪唑 、 氨 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成 2-环丙基乙酰胺
  参考文献：
  名称：

  [EN] SMALL MOLECULE VE-PTP INHIBITORS
  [FR] INHIBITEURS DE VE-PTP À PETITES MOLÉCULES

  摘要：

  本公开涉及能够抑制血管内皮蛋白酪氨酸磷酸酶（VE-PTP）的化合物。这些化合物还能够激活Tie2受体介导的信号传导。本公开还涉及所述化合物的药学上可接受的盐，包括含有这些化合物和/或药学上可接受的盐的药物组合物，以及利用这些化合物、药学上可接受的盐和/或含有相同成分的药物组合物治疗由VE-PTP信号传导介导的疾病和/或病况，例如由Angiopoietm/Tie2信号传导介导的疾病。

  公开号：

  WO2021257754A1

文献信息

• Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases
  申请人：Artman D. Linda

  公开号：US20060025477A1

  公开（公告）日：2006-02-02

  An isovaleramide analog having at least one of an increased potency, an increased half-life, and an increased stability compared to isovaleramide. The isovaleramide analog is a cyclic analog or a noncyclic analog. The isovaleramide analog is formulated into a pharmaceutical composition. A method of treating a central nervous system condition or disease is also disclosed. The method comprises administering an isovaleramide analog to a patient suffering from the central nervous system condition or disease.

  一种异戊酰胺类似物，相比异戊酰胺，至少具有增强的效力、延长的半衰期和增强的稳定性中的一种。该异戊酰胺类似物是环状类似物或非环状类似物。该异戊酰胺类似物被制成药物组合物。还揭示了一种治疗中枢神经系统疾病或疾病的方法。该方法包括向患有中枢神经系统疾病或疾病的患者施用异戊酰胺类似物。
• ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS
  申请人：Yamagishi Tatsuya

  公开号：US20140336377A1

  公开（公告）日：2014-11-13

  The present invention relates to arylamide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及一种芳基酰胺衍生物，其具有阻断电压门控钠通道（如TTX-S通道）的活性，并且在涉及电压门控钠通道的疾病和疾病的治疗或预防中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在涉及电压门控钠通道的这种疾病的预防或治疗中的使用。
• Arylamide derivatives as TTX-S blockers
  申请人：Yamagishi Tatsuya

  公开号：US09302991B2

  公开（公告）日：2016-04-05

  The present invention relates to arylamide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及芳基酰胺衍生物，其具有阻断电压门控钠通道（TTX-S通道）的活性，并且在治疗或预防涉及电压门控钠通道的疾病和疾病方面有用。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及电压门控钠通道的疾病方面使用这些化合物和组合物。
• A New Synthesis of Naphthyridinones and Quinolinones:  Palladium-Catalyzed Amidation of <i>o</i>-Carbonyl-Substituted Aryl Halides
  作者：Peter J. Manley、Mark T. Bilodeau

  DOI：10.1021/ol049165t

  日期：2004.7.1

  An alternative to the Friedlander condensation for the synthesis of naphthyridinones and quinolinones has been discovered. Palladium-catalyzed amidation of halo aromatics substituted in the ortho position by a carbonyl functional group or its equivalent with primary or secondary amides leads to the formation of substituted naphthyridinones and quinolinones.
• Inhibition of the mammalian .beta.-lactamase renal dipeptidase (dehydropeptidase-I) by Z-2-(acylamino)-3-substituted-propenoic acids
  作者：Donald W. Graham、Wallace T. Ashton、Louis Barash、Jeannette E. Brown、Ronald D. Brown、Laura F. Canning、Anna Chen、James P. Springer、Edward F. Rogers

  DOI：10.1021/jm00389a018

  日期：1987.6

  The title enzyme deactivates the potent carbapenem antibiotic imipenem in the kidney, producing low antibiotic levels in the urinary tract. A series of (Z)-2-(acylamino)-3-substituted-propenoic acids (3) are specific, competitive inhibitors of the enzyme capable of increasing the urinary concentration of imipenem in vivo. Many of the compounds were prepared in one step from an alpha-keto acid and a primary amide. The optimum R2 groups are 2,2-dimethyl, -dichloro, and -dibromocyclopropyl. With R2 = 2,2-dimethylcyclopropyl (DMCP), a wide variety of R3 groups including alkyl, oxa- and thiaalkyl, and alkyl groups containing acidic, basic, and neutral substituents give effective inhibitors with Ki values of 0.02-1 microM and a range of pharmacokinetic properties. By resolution of enantiomers and X-ray crystallography, the enzyme-inhibitory activity of the DMCP group was found to reside with the 1S isomer. The cysteinyl compound 176 (cilastatin, MK-0791) has the desired pharmacological properties and has been chosen for combination with imipenem.